News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
735,904 Results
Type
Article (41736)
Company Profile (206)
Press Release (693949)
Multimedia
Podcasts (105)
Webinars (15)
Section
Business (210039)
Career Advice (1938)
Deals (35190)
Drug Delivery (123)
Drug Development (79892)
Employer Resources (157)
FDA (16152)
Job Trends (15402)
News (349062)
Policy (32999)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Standard (1)
Academia (2757)
Accelerated approval (35)
Adcomms (27)
Allergies (154)
Alliances (46414)
ALS (181)
Alzheimer's disease (1753)
Antibody-drug conjugate (ADC) (350)
Approvals (16426)
Artificial intelligence (584)
Autoimmune disease (179)
Automation (42)
Bankruptcy (332)
Best Places to Work (12324)
BIOSECURE Act (23)
Biosimilars (206)
Biotechnology (145)
Bladder cancer (165)
Brain cancer (64)
Breast cancer (674)
Cancer (5127)
Cardiovascular disease (453)
Career advice (1581)
Career pathing (25)
CAR-T (304)
CDC (39)
Celiac Disease (1)
Cell therapy (826)
Cervical cancer (38)
Clinical research (68521)
Collaboration (1874)
Company closure (4)
Compensation (1209)
Complete response letters (70)
COVID-19 (2521)
CRISPR (101)
C-suite (927)
Cystic fibrosis (151)
Data (6453)
Decentralized trials (2)
Denatured (26)
Depression (153)
Diabetes (531)
Diagnostics (7162)
Digital health (53)
Diversity (7)
Diversity, equity & inclusion (40)
Drug discovery (291)
Drug pricing (182)
Drug shortages (30)
Duchenne muscular dystrophy (239)
Earnings (99528)
Editorial (59)
Employer branding (21)
Employer resources (126)
Events (129713)
Executive appointments (1054)
FDA (19423)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1576)
Gene editing (216)
Generative AI (52)
Gene therapy (652)
GLP-1 (1066)
Government (5041)
Grass and pollen (8)
Guidances (388)
Healthcare (20693)
HIV (66)
Huntington's disease (49)
IgA nephropathy (88)
Immunology and inflammation (299)
Immuno-oncology (61)
Indications (116)
Infectious disease (2821)
Inflammatory bowel disease (210)
Inflation Reduction Act (14)
Influenza (127)
Intellectual property (261)
Interviews (327)
IPO (17216)
IRA (52)
Job creations (3429)
Job search strategy (1378)
JPM (64)
Kidney cancer (17)
Labor market (91)
Layoffs (612)
Leadership (19)
Legal (7745)
Liver cancer (98)
Longevity (15)
Lung cancer (690)
Lymphoma (389)
Machine learning (41)
Management (44)
Manufacturing (845)
MASH (174)
Medical device (14810)
Medtech (14869)
Mergers & acquisitions (19143)
Metabolic disorders (1365)
Multiple sclerosis (173)
NASH (20)
Neurodegenerative disease (352)
Neuropsychiatric disorders (101)
Neuroscience (3092)
Neurotech (1)
NextGen: Class of 2026 (7102)
Non-profit (5056)
Now hiring (52)
Obesity (652)
Opinion (256)
Ovarian cancer (171)
Pain (215)
Pancreatic cancer (242)
Parkinson's disease (303)
Partnered (27)
Patents (526)
Patient recruitment (518)
Peanut (61)
People (58356)
Pharmaceutical (44)
Pharmacy benefit managers (29)
Phase 1 (21417)
Phase 2 (30310)
Phase 3 (22744)
Pipeline (5562)
Policy (264)
Postmarket research (2196)
Preclinical (8989)
Press Release (71)
Prostate cancer (254)
Psychedelics (54)
Radiopharmaceuticals (304)
Rare diseases (916)
Real estate (5777)
Recruiting (61)
Regulatory (24841)
Reports (59)
Research institute (2520)
Resumes & cover letters (341)
Rett syndrome (27)
RNA editing (16)
RSV (87)
Schizophrenia (159)
Series A (263)
Series B (203)
Service/supplier (9)
Sickle cell disease (104)
Special edition (28)
Spinal muscular atrophy (166)
Sponsored (34)
Startups (3372)
State (2)
Stomach cancer (18)
Supply chain (109)
Tariffs (69)
The Weekly (78)
Vaccines (1024)
Venture capital (96)
Weight loss (437)
Women's health (88)
Worklife (14)
Date
Today (154)
Last 7 days (649)
Last 30 days (2459)
Last 365 days (32063)
2026 (4066)
2025 (32450)
2024 (37312)
2023 (42381)
2022 (53017)
2021 (57342)
2020 (56695)
2019 (50583)
2018 (37408)
2017 (33677)
2016 (33120)
2015 (38525)
2014 (31629)
2013 (26798)
2012 (28035)
2011 (28758)
2010 (25654)
Location
Africa (750)
Alabama (91)
Alaska (7)
Arizona (275)
Arkansas (14)
Asia (43681)
Australia (7149)
California (11697)
Canada (3381)
China (1186)
Colorado (496)
Connecticut (508)
Delaware (349)
Europe (98083)
Florida (1752)
Georgia (378)
Hawaii (3)
Idaho (63)
Illinois (928)
India (72)
Indiana (551)
Iowa (22)
Japan (448)
Kansas (126)
Kentucky (42)
Louisiana (27)
Maine (84)
Maryland (1463)
Massachusetts (8568)
Michigan (356)
Minnesota (666)
Mississippi (6)
Missouri (141)
Montana (36)
Nebraska (28)
Nevada (128)
New Hampshire (85)
New Jersey (3159)
New Mexico (32)
New York (3105)
North Carolina (1600)
North Dakota (10)
Northern California (5714)
Ohio (361)
Oklahoma (23)
Oregon (45)
Pennsylvania (2341)
Puerto Rico (25)
Rhode Island (47)
South America (1139)
South Carolina (68)
South Dakota (1)
Southern California (4581)
Tennessee (181)
Texas (1820)
United States (42027)
Utah (352)
Vermont (1)
Virginia (284)
Washington D.C. (79)
Washington State (967)
West Virginia (4)
Wisconsin (127)
Wyoming (2)
735,904 Results for "20".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
November 6, 2025
·
3 min read
·
Heather McKenzie
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Press Releases
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
February 12, 2026
·
5 min read
Press Releases
Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026
February 13, 2026
·
1 min read
Press Releases
MustGrow Closes $2.0 Million Non-Brokered LIFE Offering
January 23, 2026
·
5 min read
Press Releases
Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF)
February 18, 2026
·
3 min read
Press Releases
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
February 11, 2026
·
6 min read
Layoffs
Vedanta Downsizes by 20% After Phase II Stumble in Ulcerative Colitis
Vedanta is parting ways with 23 employees, or approximately 20% of its headcount, after Phase II data for microbiome therapy VE202 failed to demonstrate significant response rates in patients with ulcerative colitis.
August 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
January 21, 2026
·
29 min read
Press Releases
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
February 10, 2026
·
5 min read
1 of 73,591
Next
